These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
725 related articles for article (PubMed ID: 30170630)
1. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630 [TBL] [Abstract][Full Text] [Related]
2. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy. Tan I; Malinzak M; Salama AKS J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495 [TBL] [Abstract][Full Text] [Related]
3. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab. Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688 [TBL] [Abstract][Full Text] [Related]
4. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma. Alnabulsi R; Hussain A; DeAngelis D Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409 [TBL] [Abstract][Full Text] [Related]
5. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma. Liu Y; Liu Z; Zeng X; Bai C; Chen L; Lin S; Tian X BMC Cancer; 2019 Dec; 19(1):1193. PubMed ID: 31805889 [TBL] [Abstract][Full Text] [Related]
6. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807 [TBL] [Abstract][Full Text] [Related]
7. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis. Abdelhafeez AAM; Shohdy KS; Ibrahim W Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260 [TBL] [Abstract][Full Text] [Related]
8. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report. Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109 [TBL] [Abstract][Full Text] [Related]
9. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy. Gambichler T; Stockfleth E; Susok L J Immunother Cancer; 2018 Oct; 6(1):113. PubMed ID: 30376886 [TBL] [Abstract][Full Text] [Related]
10. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. Gao CA; Weber UM; Peixoto AJ; Weiss SA J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673 [TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873 [TBL] [Abstract][Full Text] [Related]
13. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206 [TBL] [Abstract][Full Text] [Related]
14. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646 [TBL] [Abstract][Full Text] [Related]
15. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992 [TBL] [Abstract][Full Text] [Related]
16. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma. Lasocki A; Smith K J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645 [TBL] [Abstract][Full Text] [Related]
17. Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature. Khoury ZH; Hausner PF; Idzik-Starr CL; Frykenberg MRA; Brooks JK; Dyalram D; Basile JR; Younis RH J Immunother; 2019 Oct; 42(8):313-317. PubMed ID: 31206394 [TBL] [Abstract][Full Text] [Related]
18. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases. Zieman D; Frankel AE J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723 [TBL] [Abstract][Full Text] [Related]
19. Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy. Hoogland AI; Brohl AS; Small BJ; Michael L; Wuthrick E; Eroglu Z; Blakaj D; Verschraegen C; Khushalani NI; Jim HSL; Kim S Cancer Med; 2024 Jul; 13(14):e7464. PubMed ID: 39021272 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report. Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]